[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Hutchmed (china) Limited LSE:HCM London Ordinary Share KYG4672N1198 ORD USD0.10
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 567.00 550.00 564.00 - 200 08:02:50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 166.7 -138.8 -13.2 - 4,901

Hutchmed (china) Share Discussion Threads

Showing 3401 to 3424 of 3500 messages
Chat Pages: 140  139  138  137  136  135  134  133  132  131  130  129  Older
DateSubjectAuthorDiscuss
19/7/2021
15:37
Just amazing to see HCM the only BLUE in a see of RED in my 53-strong list of shares I watch, - changed days indeed!
fionascott1234
18/7/2021
18:09
Yet another publication warning US investors about Chinese-listed stocks: (It's from Barrons. I don't like to infringe copyright but can't stand R Murdoch and his role in spreading fake news, so don't feel too bad about the copy and paste.) Anyway, I'm just really glad we're now listed in HK.... The giant “caution”; sign for investors who own Chinese stocks has been blinking for months. It’s about to become a blaring beacon of warning. Individual investors who still own, or are considering owning, individual shares of U.S.-listed Chinese stocks need to heed this warning. Barron’s has been writing about the challenges that face Chinese companies on multiple fronts: Beijing has steadily intensified the regulatory scrutiny of its largest technology companies, while U.S.-China tensions escalate and prompt investment restrictions and legislation that create further market ramifications. Yes, the case for investing in China is strong, especially over the long run. China’s rapid economic growth is generally appealing, and has led to a burgeoning middle class that has, in turn, allowed many nascent industries to blossom. Plus, many of China’s homegrown technology companies benefit from government investment, and U.S.-China tensions. But as Barron’s wrote earlier this month, the way to navigate this landscape is by hiring a tour guide in the form of a mutual fund or exchange-traded fund manager that can manage growing complexities. Each week makes that case even stronger. Owning individual shares of Chinese companies listed in the U.S.—whether they’re traded over the counter (rather than on a major exchange) or as American Depositary Receipts (ADRs)—could increasingly become a risky proposition. Institutional investors who have the option of owning shares on a Hong Kong or mainland China stock exchange are well on their way to that transition—which could add pressure to U.S.-listed shares and eventually cause liquidity problems. The ADR-heavy Invesco Golden Dragon exchange-traded fund (PGJ) is down 13% in the last three months. The iShares MSCI China (MCHI), which also owns Hong Kong-listed shares, is down 4%, and the iShares MSCI China A-shares (CNYA), which focuses on China-listed companies, is up 7%. The latest cloud looming over U.S.-listed Chinese companies is uncertainty around how U.S. regulators will enforce last year’s Holding Foreign Companies Accountable Act, which requires foreign companies to adhere to U.S. auditing standards in order to trade on U.S. exchanges. The Chinese government has long prevented Chinese companies from providing the necessary information to comply with U.S. auditing requirements. The process toward enforcement is underway; the feedback period for a Public Company Accounting Oversight Board (PCAOB) proposal closes this week, and policy watchers expect a rule to be released soon. A PCAOB spokeswoman declined to comment. The rule will pave the way for the Securities and Exchange Commission to enforce the legislation. Currently there is a three year-window for compliance; the Senate last month passed a bill that would accelerate the timeline to just two years—another indication of the bipartisan support for China measures. Despite policy makers’ urgency, policy watchers note a lot of outstanding questions. There are some 248 Chinese companies listed on U.S. exchanges with a combined market value of more than $2 trillion—so the process of delisting could be messy and painful. “If a delisting is imminent, the stock price is going to plummet and those who control the company can buy out public investors for a bargain, go private, and relist in Asia at a much higher valuation and make a ton of money—at Americans’ expense,” says Jesse Fried, a professor at Harvard Law School who has been researching regulation of Chinese firms trading in the United States. There’s also no precedent for the type of mass delisting that could unwind in a worse-case scenario—a factor that could lead to an elusive compromise between the two nations. “Despite the ongoing, heightened tensions between the U.S. and China, this could be the last salvo bringing both sides back to the table to work out some deal where there will be just enough access to audit personnel and work papers so that the nuclear option is avoided and the PCAOB will be able to meet its core obligations under the Sarbanes-Oxley Act,” says Shas Das, counsel at King & Spalding, who was the PCAOB’s chief negotiator with Chinese regulators between 2011 and 2015. Past negotiations yielded some cooperation and access to audit work papers but not consistently, he adds. Investors would be ill-advised to wait around to see if some compromise materializes, especially as U.S.-China tensions continue to ratchet higher. On Thursday, the Senate passed a bill to ban imported products from China’s Xinjiang region amid allegations of forced-labor practices, and the U.S. has been adding Chinese companies to a blacklist, cutting them off from U.S. investment. Investors got a painful glimpse at the havoc these measures can cause when widely held China Mobile was delisted in January by the New York Stock Exchange, following an executive order from President Donald Trump banning investment in companies the U.S. said had ties to China’s military. Institutional investors were able to convert into Hong Kong-listed shares, but many retail investors have been stuck in limbo—even now, many investors cannot execute a sale at their current broker, and some are being told to seek out foreign brokers. Others have run into dead-ends with no clarity on who to reach out to for assistance, and face being stuck with a loss. The SEC didn’t respond to a request for comment.
nahoon
16/7/2021
06:18
Wonderful news today that an MAA has been submitted to the EMA for Sulanda® who have up to a maximum of 210 days to make a decision so approval could be by early 2022. It will be interesting to see what partnership/commercial deal Hutchmed get to handle the sales of Sulanda® in Europe. Https://www.ema.europa.eu/en/documents/leaflet/applying-european-union-marketing-authorisation-medicinal-products-human-use_en.pdf
nerdofsteel
15/7/2021
10:06
Would be nice, resisted temptation to sell out over 600p, still hopeful this has scope to double or triple if drug delivery goes to plan.
its the oxman
15/7/2021
09:51
563p equiv HK.The more erratic period of price performance seems to be subsiding.Hopefully,we can enjoy a steadier build from chart bottom left to top right
steeplejack
14/7/2021
18:39
He is principal at Barings….and seems to hold these through Barings…I think this reflects a top up in the recent listing rather than a new investor.
whatja
14/7/2021
14:50
And one who is based in HK; RNS appears to have been after the close in HK so possible positive reaction overnight.
mcmather
14/7/2021
14:41
Billionaire takes 3% stake.
cockneytrader
13/7/2021
09:57
HM is going to be flooded with cash over the next few years . That is what will overcome the ‘Chinese Company’, lack of takeover premium etc and drive the share price.
dbadvn
13/7/2021
07:48
Good for AZN…..not hanging around. 30% to HCM straight to bottom line.
whatja
13/7/2021
05:28
Some good news from HCM under the announcements tab over on the HKEX: Https://www1.hkexnews.hk/listedco/listconews/sehk/2021/0713/2021071300047.pdf VOLUNTARY ANNOUNCEMENT – First Commercial Sale of ORPATHYS®in China, Triggering a US$25 million Milestone Payment from AstraZeneca HUTCHMED (China) Limited (“HUTCHMED”) announcesthe first commercial sale in China of ORPATHYS®(savolitinib), HUTCHMED’s oral, potent, and highly selective small molecule inhibitor of MET, a receptor tyrosine kinase, which occurred on July 12, 2021.
lauders
08/7/2021
09:17
533p HK close
steeplejack
06/7/2021
19:34
hxxps://www.wsj.com/articles/china-to-revise-rules-and-strengthen-supervision-of-overseas-listings-11625572533?st=l523pvukowp10om&reflink=desktopwebshare_permalink Probably scared the US listing, now down 14%. Long sigh....
nahoon
06/7/2021
18:04
Trading volume will be dominated by HK and eventually Shanghai in any case.
dbadvn
06/7/2021
17:48
They have already suffered. As an example I have a 401K and the rules of the scheme specifically prohibit the Fund Managers from investing in any Chinese Companies.
nerdofsteel
06/7/2021
15:49
Well,you’re right. What an irritating stock this is to hold. “China said it would tighten rules for com­pa­nies seek­ing to sell shares abroad and strengthen over­sight of over­seas-listed com­pa­nies, moves that could hin­der at­tempts by home­grown firms to raise money in the U.S.”WSJ 6th July 2021 This news today in the Wall St Journal is the start of an article discussing the increasing tensions between the US and China.Its probable that Hutchmed decided to get on with an HK listing in awareness that life could become much more difficult for Chinese companies wanting to raise money in the US,especially for tech companies,not just because of US moves but because of moves by the Chinese Government.If things get worse,Chinese companies could find a lack of US investor appetite for the equity of Chinese listed companies.Yet,happily,the recent HK listing of Hutchmed attracted excellent North American backing but going forward things might not be so benign.
steeplejack
06/7/2021
13:59
Oh really?Well no surprise that it will finish sub-£5 here then.
fionascott1234
06/7/2021
12:23
Updated Trinity Delta valuation of 802p now. Https://www.trinitydelta.org/research-notes/asco-2021-moving-towards-combinations/ US$52.12/ADS or 802p/HK$81.30/share valuation Following the Hong Kong IPO and global offering, and recent China approvals of surufatinib (pNET) and savolitinib (NSCLC MET ex14m), our updated HUTCHMED valuation is US$8.84bn (US$52.12 per ADS), £6.8bn (802p per share), or HK$69.0bn (HK$81.30 per share). Details are available in our July 2021 Update. Clinical, regulatory, and commercial progress and the planned expansion of the clinical pipeline could unlock further value.
lauders
06/7/2021
07:32
HK closed at 521p equiv.
steeplejack
06/7/2021
04:25
HUTCHMED Initiates Phase I Trials of novel ERK inhibitor HMPL‑295 in Patients with Advanced Solid Tumors in China Https://www.hutch-med.com/wp-content/uploads/2021/07/a210706.pdf
lauders
05/7/2021
09:13
553p close in HK
steeplejack
05/7/2021
09:03
Well got my timing totally right, for once, buying hcm on the dip. Happy to have sold up here on the HK ipo.
miti 1000
02/7/2021
12:36
That is a big chunk acquired by The Carlyle Group Inc.
mcmather
02/7/2021
08:30
Agreed.I wonder where the MM s keep their bag of numbers to manipulate the HCM price particularly that of the closing price.
fionascott1234
Chat Pages: 140  139  138  137  136  135  134  133  132  131  130  129  Older
ADVFN Advertorial
Your Recent History
LSE
HCM
Hutchmed (..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210922 07:22:00